Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 17 (TRAV17) is a variable (V) region segment of the T cell receptor (TCR) alpha chain gene, which encodes the antigen-binding domain of the TCR found on the surface of T lymphocytes[1][3][4]. TRAV17 contributes to the immune system’s capacity to recognize diverse peptide antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[1][2][4]. The TCR is essential for the activation of T cells and the adaptive immune response; its engagement leads to intracellular signaling cascades that drive T cell activation, proliferation, and effector functions[1][2]. TRAV17 is one of dozens of such V region segments that combine stochastically with joining (J) and constant (C) regions to create TCR diversity via somatic recombination in the thymus[1][2]. As with other V segments, TRAV17 is not directly a therapeutic target but forms part of the repertoire that enables T cell–mediated antigen recognition and responses[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 17 (TRAV17).